Valeant Pharmaceuticals International, Inc.
) announced that the FDA issued a marketing clearance for Restylane
Silk Injectable Gel with 0.3% Lidocaine.
Restylane Silk Injectable Gel is indicated for submucosal
implantation for lip augmentation and dermal implantation for
correction of perioral rhytids in patients over the age of 21.
Valeant had conducted a clinical study (n=221) on Restylane to
evaluate the safety and effectiveness of injections among females
with light and dark skin to enhance lip fullness and to improve
wrinkles around the lips.
As observed in the study data, 98% of subjects reported
improvement in their lip fullness 14 days after injection and 76%
of the subjects still had lip improvement 6 months after their
We remind investors that in May 2014, Valeant entered into an
agreement with Nestle S.A to sell its rights of Restylane, Perlane,
Emervel, Sculptra, and Dysport for $1.4 billion in cash.
Valeant had acquired rights to aesthetics products such as
Dysport, Perlane, and Restylan through its acquisition of Medicis
in Dec 2012.
Earlier in the month, the FDA approved Valeant's New Drug
Application (NDA) for Jublia (efinaconazole 10% topical solution)
for the treatment of onychomycosis of the toenails.
Meanwhile, Valeant is engaged in a patent infringement suit with
) for Restylane and Perlane dermal filler products. Allergan has
accused Valeant of infringing some of its patents in the U.S.
We note that Allergan recently rejected the revised acquisition
offer by Valeant and Pershing Square Capital Management.
Valeant currently has a Rank #3 (Hold). Investors looking for
better-ranked stocks in the healthcare sector may consider
Forest Laboratories Inc.
). While Gilead Sciences carries a Zacks Rank #1 (Strong Buy),
Forest Labs is a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
FOREST LABS A (FRX): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.